Nkarta (NKTX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered NK cell therapies for autoimmune diseases and other indications.

• Lead program, NKX019, is a CAR NK product targeting CD19 antigen, currently in Phase 1 trials for multiple autoimmune diseases.

• Proprietary platform enables scalable, on-demand manufacturing of NK cells from healthy donors, aiming for broad patient access and improved safety over autologous therapies.

• Oncology programs have been deprioritized to focus resources on autoimmune disease pipeline.

Financial performance and metrics

• As of March 18, 2026, 74,290,521 shares of common stock were issued and outstanding, including 3,000,031 shares underlying pre-funded warrants.

• No preferred stock was outstanding as of that date.

Use of proceeds and capital allocation

• Net proceeds from securities sales will fund research, development, and manufacturing of product candidates, advance the NK cell therapy platform, increase working capital, fund capital expenditures, and for general corporate purposes.

• Pending specific use, proceeds may be invested in short-term investments, including marketable securities.